Extended duration ganaxolone treatment for seizures associated with CDKL5 Deficiency Disorder: 1-year minimum open-label extension follow-up

被引：0
|
作者：
Pestana-Knight, E.
Demarest, S.
Devinsky, O.
Amin, S.
Aimetti, A.
Rybak, E.
Miller, I
Hulihan, J.
Olson, H.
机构：
来源：
ANNALS OF NEUROLOGY | 2022年 / 92卷
关键词：
Epilepsy/Sleep; Rare Diseases; Genetics;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
40
引用
收藏
页码：S72 / S73
页数：2
相关论文
共 50 条
  • [1] Long-term treatment with ganaxolone for seizures associated with CDKL5 Deficiency Disorder: 2-year open-label extension follow-up
    Miller, I
    Demarest, S.
    Bahi-Buisson, N.
    Pestana-Knight, E.
    Devinsky, O.
    Amin, S.
    Marsh, E.
    Aimetti, A.
    Hulihan, J.
    Olson, H.
    ANNALS OF NEUROLOGY, 2023, 94 : S63 - S63
  • [2] Long-term treatment with ganaxolone for seizures associated with CDKL5 deficiency disorder: 2-year open-label extension follow-up
    Bahi-Buisson, N.
    Olson, H.
    Pestana-Knight, E.
    Devinsky, O.
    Amin, S.
    Marsh, E.
    Aimetti, A.
    Miller, I.
    Hulihan, J.
    Demarest, S.
    EPILEPSIA, 2023, 64 : 158 - 158
  • [3] Extended duration safety and efficacy of adjunctive ganaxolone treatment in patients with CDKL5 deficiency disorder: 8-month minimum open-label extension follow-up
    Olson, H.
    Moosa, A.
    Rybak, E.
    Aimetti, A.
    Hulihan, J.
    Pestana-Knight, E.
    EPILEPSIA, 2022, 63 : 235 - 236
  • [4] Ganaxolone for management of seizures associated with CDKL5 deficiency disorder
    Yasmen, Nelufar
    Sluter, Madison N.
    Yu, Ying
    Jiang, Jianxiong
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2023, 44 (02) : 128 - 129
  • [5] Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up
    Olson, Heather E.
    Amin, Sam
    Bahi-Buisson, Nadia
    Devinsky, Orrin
    Marsh, Eric D.
    Pestana-Knight, Elia
    Rajaraman, Rajsekar R.
    Aimetti, Alex A.
    Rybak, Eva
    Kong, Fanhui
    Miller, Ian
    Hulihan, Joseph
    Demarest, Scott
    EPILEPSIA, 2024, 65 (01) : 37 - 45
  • [6] Effect of concomitant antiseizure medications on the safety and efficacy of ganaxolone for the treatment of seizures associated with CDKL5 Deficiency Disorder (CDD): Findings from the Phase 3 MARIGOLD Study
    Flatt, J.
    Rajaraman, R.
    Amin, S.
    Aimetti, A.
    Hulihan, J.
    Perry, M. S.
    ANNALS OF NEUROLOGY, 2025, 96 : S44 - S44
  • [7] Design of a phase 3 clinical study to examine the efficacy and safety of fenfluramine (ZX008) in subjects with CDKL5 deficiency disorder followed by an open-label extension
    Devinsky, O.
    Olson, H. E.
    Rajaraman, R. R.
    Guerrini, R.
    Bahi-Buisson, N.
    Aledo-Serrano, A.
    Cross, J. H.
    el Baghdady, A.
    Morita, D.
    Langlois, M.
    St Wecker, P.
    EPILEPSIA, 2023, 64 : 304 - 304
  • [8] Cyclical Etidronate Therapy for Prevention of Postmenopausal Bone Loss: A 1-Year Open-Label Follow-Up Study
    I. Fogelman
    R. J. M. Herd
    G. M. Blake
    R. Balena
    Calcified Tissue International, 2000, 66 : 348 - 354
  • [9] Cyclical etidronate therapy for prevention of postmenopausal bone loss: A 1-year open-label follow-up study
    Fogelman, I
    Herd, RJM
    Blake, GM
    Balena, R
    CALCIFIED TISSUE INTERNATIONAL, 2000, 66 (05) : 348 - 354
  • [10] Ganaxolone significantly reduces major motor seizures associated with Cdkl5 Deficiency disorder: A randomized, double-blind, placebo-controlled Phase 3 study
    Pestana--Knight, E.
    Amin, S.
    Benke, T.
    Cross, H.
    Olson, H.
    Fleming, T.
    Demarest, S.
    Specchio, N.
    EPILEPSIA, 2022, 63 : 237 - 238
12345